NanoViricides, Inc. (NYSE American: NNVC) has begun enrolling and dosing patients in its Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus and other Ebola viruses, the company announced. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC), with the Phase IIA portion starting enrollment and dosing around September 23. This development matters because it represents a critical milestone in the clinical advancement of a novel broad-spectrum antiviral candidate, potentially offering a new oral treatment option for Ebola, a disease with limited therapeutic options and high mortality rates.
The Phase IIA portion is designed to establish a safe and well-tolerated dosing protocol for NV-387, which will then be used in the Phase IIB portion to evaluate the drug's safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. For NanoViricides, a clinical-stage company creating special purpose nanomaterials for antiviral therapy, the start of patient dosing is a significant operational achievement. The company's lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for respiratory viral infections such as RSV, COVID, and influenza, as well as for MPOX/Smallpox and measles. Advancing NV-387 into Phase II human trials for Ebola not only validates the platform's potential against a deadly virus but also could accelerate development across other indications.
The broader implications for investors and the biotech sector are noteworthy. Ebola outbreaks in regions like the DRC pose global health threats, and an oral gummy formulation could be easier to administer in resource-limited settings compared to injectable therapies. If successful, NV-387 could become a key tool in outbreak response. The company's business model relies on licensing technology from TheraCour Pharma, Inc., and its nanoviricide technology is based on proprietary intellectual property. NanoViricides holds broad, exclusive licenses for several viral diseases, including Ebola/Marburg, HIV, Hepatitis, and Influenza. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. To view the full press release, visit https://ibn.fm/qC4Hk.
MissionIR, a specialized communications platform, distributed the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit MissionIR and IBN. As with any drug development, there can be no assurance that NV-387 will show sufficient effectiveness and safety for human clinical development. The path to typical drug development is lengthy and requires substantial capital. Nevertheless, the initiation of this trial underscores the urgent need for new Ebola treatments and highlights NanoViricides' progress in advancing its pipeline.
